Pharmaceuticals, Biotechnology & Life Sciences

Omeros Corp. completes primate study for OncotoX‑AML™—a critical step toward targeted AML therapy, boosting investor interest amid volatile biotech markets.

Jaguar Health’s new one‑time stock dividend shows its commitment to shareholders amid a challenging financial climate, highlighting its natural‑pharma focus and future growth prospects.

Vistagen Therapeutics faces a federal securities class action while gearing up to present its intranasal “pherines” at the TD Cowen Healthcare Conference, leaving investors to weigh legal risks against potential neuropharmacology breakthroughs and a…

Opus Genetics reports promising Phase 1/2 BEST1 gene‑therapy results and FDA acceptance of a new phentolamine eye solution for presbyopia, boosting its vision‑therapy pipeline.

ALX Oncology’s 2025 results show a return to profitability, a $150 million capital raise, and promising progress in evorpacept and ALX2004 trials – key insights for investors and oncology stakeholders.

Discover Photocure ASA: Norway’s pharma leader behind Hexvix, Cevira and Visonac, its market outlook, stock insights, and future growth potential.

AbbVie 2026 outlook: high‑cap pharma leader with $380 m manufacturing expansion, AI‑driven pipeline, and “Outperform” analyst support—investors weigh robust growth vs. lofty PE.

Discover how Anavex Life Sciences, a Nasdaq‑listed biotech, is accelerating precision genetic medicine for severe neurological disorders with its lead candidate, ANAVEX®2‑73, and new leadership insights from the upcoming TD Cowen Health Care Confere…

Explore Puma Biotechnology’s strategy to repurpose early‑stage cancer therapies, its recent Nasdaq rebound, and key investment metrics for 2026.

REGENXBIO’s March 5 2026 conference call will reveal Q4‑2025 earnings, pipeline progress, and strategic plans, offering investors a clear view of its biotech growth.